Study Highlights
Based on a 12-week placebo-controlled triple-blind study showing promising trends toward improved comfort in daily activities (-23.39% vs. -9.17% placebo) and IL-6 levels, though not statistically significant. More research is needed.*
*Results did not yield statistical significance
**FDA disclaimer
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The results showed encouraging trends, though not statistically significant. *
Compared to baseline
In the study, participants using Remedolor began to notice changes as early as Week 8, with 72% agreeing to less joint discomfort, 68.97% reporting less back discomfort, and 65.52% noting reduced use of painkillers compared to their baseline levels. By Week 12, these trends became more pronounced, as participants reported up to 40.85% less back discomfort, 39.77% better joint comfort, and a notable 32.38% increase in satisfaction with their daily activities. Additionally, they experienced 28.04% less stiffness and 29.23% reduced painkiller usage.
Compared to placebo
We highlight these areas for you to note where Remedolor® showed promising trends. However, the overall study outcome was not statistically significant.
At Movzu™, we went the extra mile to rigorously test our product. We conducted a triple-blind, placebo-controlled clinical trial — one of the highest standards in research — where neither the participants, the researchers, nor the data analysts knew who was getting the real supplement or a placebo.
While the overall results in this particular study did not reach statistical significance, we still completed this thorough testing process. That’s more than most supplements on the market can claim.
We’re proud of our commitment to real science and transparency, and we’re using what we learned to keep improving. As always, talk to your doctor before starting any new supplement.
A -23.39% decrease in the frequency of traditional painkiller use (vs. -9.17% placebo) highlights a potential benefit in reducing dependence on medications like Tylenol or NSAIDs, appealing to those seeking non-pharmaceutical alternatives.*
At 12 weeks, a -23.68% improvement in satisfaction with day-to-day activity levels (vs. -4.40% placebo) suggests Remedolor may help users feel more content with their mobility and routine.
Satisfaction with activity levels means how happy you feel about doing your daily tasks—like cleaning or walking—without joint discomfort holding you back. In the study, Remedolor users reported up to 32% more satisfaction by Week 12.
"IL-6 is a natural substance in your body that can increase when joints experience inflammation or discomfort, often seen in conditions like everyday wear and tear or stiffness. Keeping IL-6 levels in check may support healthier, more comfortable joints. By Week 12, the test group (Remedolor) demonstrated reduced IL-6 levels by -2.31%—a beneficial decrease in this common joint inflammation marker—while the placebo group showed a significant increase of +16.95%, resulting in a ~19% better outcome for the test group.